nLife Therapeutics Enters Research Collaboration with WAVE Life Sciences to Explore Targeting of Nucleic Acids to Specific Cell-Types in the Central Nervous System
(Thomson Reuters ONE) -
GRANADA, Spain, March, 3rd, 2017 - nLife Therapeutics S.L., an early-stage
biopharmaceutical company developing chemical conjugates technologies, today
announced the initiation of a research collaboration aimed at exploring cell-
specific targeting of nucleic-acid therapeutics in the central nervous system
(CNS) with WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company
focused on developing therapies for patients impacted by rare genetic diseases.
Over the next two years, nLife and WAVE will assess the ability of several
chemical moieties to direct distribution and uptake of nucleic acid cargo to
specific cell-types within the CNS, including neurons, glia and astrocytes.
nLife is developing conjugates of small molecules and oligonucleotides that
direct the delivery to specific cells in a selective manner. WAVE's fully
integrated platform enables the design and development of stereopure nucleic
acid therapeutics, with optimized efficacy, stability, safety, and specificity.
Per the agreement, WAVE will fund the research activities at nLife and has the
option to license nLife's technology for development and commercialization
rights across the WAVE portfolio.
Errol De Souza, Executive Chairman of nLife Therapeutics, said, "By combining
WAVE's stereopure molecules with our targeted delivery technology, we believe it
will be possible to address genetic diseases that were previously not accessible
and potentially expand development of safe and effective treatments for a host
of CNS disorders."
"Following promising broad distribution of our existing CNS programs, and as we
expand our portfolio into additional neurological disorders, we are exploring
the ability of various technologies to selectively target certain cell types.
This collaboration reflects WAVE's long-term commitment to neurology and we
expect will complement our oligonucleotide expertise within the CNS space" said
Paul Bolno, M.D., MBA, President, and Chief Executive Officer of WAVE Life
Sciences. "We are excited to initiate this research collaboration with nLife, a
company that we believe is at the forefront of neuronal targeting technologies."
---
Media and Investor Contacts:
Investor inquiries - nLife Therapeutics
Andrés Montefeltro - Senior VP, Research Head & Founder
amontefeltro(at)n-life.es
Media liaison - BN1 communications
Sarah Morgan | sarahbn1(at)hotmail.com | +44 (0)7789 956966
About nLife Therapeutics and its nucleic acid delivery platform technology
Founded in 2010 and based in Granada (Spain), nLife Therapeutics is leading the
development of cell-specific oligonucleotides as therapeutic agents for central
nervous system and neuromuscular disorders. Oligonucleotides are short nucleic
acid polymers designed to bind to specific complementary messenger RNA strands
promoting their degradation, which produces a decrease in the levels of specific
proteins that may contribute to diseases when they accumulate. Selective
delivery and cell-specific targeting are achieved by attaching small molecule
chemical ligands to the oligonucleotide. The conjugated oligonucleotides can be
applied to un-druggable target proteins and have potential as a disease-
modifying therapy for a broad array of genetic disorders that might otherwise
have no viable treatment option.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: nLife Therapeutics S.L. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 03.03.2017 - 08:50 Uhr
Sprache: Deutsch
News-ID 527938
Anzahl Zeichen: 4087
contact information:
Town:
Armilla, Granada
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 233 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"nLife Therapeutics Enters Research Collaboration with WAVE Life Sciences to Explore Targeting of Nucleic Acids to Specific Cell-Types in the Central Nervous System"
steht unter der journalistisch-redaktionellen Verantwortung von
nLife Therapeutics S.L. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
